Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase I Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV

NCT01683682 is registered in ClinicalTrials.gov with Aktion Bronchialkarzinom e.V. as lead sponsor.

NCT NCT01683682
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01683682 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase I Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV
Lead sponsor
Aktion Bronchialkarzinom e.V.
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2013
Completion date
Not reported
Enrollment
8 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung